|
|
|
|
| LEADER |
05367nam a2200637 4500 |
| 001 |
ocn946105667 |
| 003 |
OCoLC |
| 005 |
20180501122030.0 |
| 006 |
m o d |
| 007 |
cr |n||||||||| |
| 008 |
160408s2016 maua ob 001 0 eng d |
| 040 |
|
|
|a IDEBK
|b eng
|e pn
|c IDEBK
|d N$T
|d YDXCP
|d EBLCP
|d N$T
|d OCLCF
|d CDX
|d OPELS
|d OCLCQ
|d D6H
|d GrThAP
|
| 019 |
|
|
|a 947222451
|
| 020 |
|
|
|a 9780128051818
|q (electronic bk.)
|
| 020 |
|
|
|a 0128051817
|q (electronic bk.)
|
| 020 |
|
|
|a 9780128047897
|
| 020 |
|
|
|a 0128047895
|
| 035 |
|
|
|a (OCoLC)946105667
|z (OCoLC)947222451
|
| 050 |
|
4 |
|a RC267
|
| 072 |
|
7 |
|a HEA
|x 039000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 014000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 022000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 112000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 045000
|2 bisacsh
|
| 082 |
0 |
4 |
|a 616.9940072
|2 23
|
| 049 |
|
|
|a TEFA
|
| 245 |
0 |
0 |
|a Advances in cancer research.
|n Volume one hundred and thirty /
|c edited by Kenneth D. Tew, Paul B. Fisher.
|
| 246 |
3 |
|
|a Advances in cancer research.
|n 130
|
| 250 |
|
|
|a First edition.
|
| 264 |
|
1 |
|a Cambridge, MA :
|b Academic Press is an imprint of Elsevier,
|c 2016.
|
| 300 |
|
|
|a 1 online resource :
|b color illustrations.
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 490 |
1 |
|
|a Advances in Cancer Research ;
|v v. 130
|
| 588 |
0 |
|
|a Online resource; title from PDF title page (EBSCO, viewed April 18, 2016).
|
| 504 |
|
|
|a Includes bibliographical references and index.
|
| 505 |
0 |
|
|a Front Cover; Advances in Cancer Research; Copyright; Contents; Contributors; Chapter One: The Evolving, Multifaceted Roles of Autophagy in Cancer; 1. Introduction; 2. Overview of Autophagy; 2.1. Molecular Machinery of Autophagosome Biogenesis; 2.1.1. Initiation of Autophagosome Biogenesis by the ULK Complex; 2.1.2. Nucleation of the Phagophore by the Class III PI3K Complex; 2.1.3. Elongation of the Phagophore by the mAtg12 and LC3 Conjugation Systems; 2.2. Fusion; 2.3. Regulation of Mammalian Autophagy; 2.3.1. Nutrient and Growth Factor Starvation; 2.3.2. Hypoxia; 2.3.3. Oxidative Stress.
|
| 505 |
8 |
|
|a 2.3.4. Endoplasmic Reticulum Stress2.3.5. DNA Damage; 2.3.6. Ionizing Radiation; 2.3.7. Immune System Activation; 2.3.8. Tumor Suppressor p53; 2.3.9. Epigenetic Modifications and mRNA Silencing; 2.4. Selective Capture of Autophagic Cargo in Mammals; 3. Tumor-Suppressive Roles for Autophagy in Cancer; 3.1. Genetic Basis for the Involvement of Autophagy in Tumor Suppression; 3.2. Inhibition of p62-Mediated Signaling Pathways; 3.3. Activation of Oncogene-Induced Senescence; 3.4. Maintenance of Immune Surveillance and Avoidance of Inflammation.
|
| 505 |
8 |
|
|a 3.5. Clearance of Defective Mitochondria and Maintenance of Genomic Integrity3.6. Autophagy-Inducing Agents in Cancer Therapy; 4. Tumor-Promoting Roles for Autophagy in Cancer; 4.1. Genetic Evidence for the Involvement of Autophagy in Tumor Promotion; 4.2. Autophagy Supports Metabolic Adaptation to Accommodate Increased Biosynthetic Needs; 4.3. Survival Programs, Therapeutic Resistance, and Tumor Dormancy; 4.4. Interaction with the Tumor Microenvironment; 4.5. Autophagy-Inhibiting Agents in Cancer Therapy; 5. New Intersections Between Autophagy and Secretion.
|
| 505 |
8 |
|
|a 5.1. Evidence for Autophagy-Dependent Secretion5.2. Emerging Roles for Autophagy-Dependent Secretion in Cancer; 6. Concluding Remarks and Perspectives; Acknowledgments; References; Chapter Two: Inhibitors of DNA Methylation, Histone Deacetylation, and Histone Demethylation: APerfect Combination for Ca ... ; 1. Introduction; 2. DNMTs: The Enzymes Responsible for DNA Methylation; 3. DNA-Demethylating Agents; 4. Azacytidine in RNA Metabolism; 5. Histone Acetylation; 5.1. Histone Deacetylases; 5.1.1. Class IHDACs; 5.1.2. Class II HDACs; 5.1.3. Class IV HDAC; 6. Nuclear Repressive Complexes.
|
| 505 |
8 |
|
|a 6.1. Nucleosome Remodeling and Deacetylase Complex: ALink Between DNA Methylation, Histone Deacetylation, and Nucleosome ... 6.2. NCoR and SMRT Corepressor Complex; 6.3. Corepressor of RE1-Silencing Transcription Factor (CoREST) Repressor Complex; 7. HDAC Inhibitors: General Mechanism of Zinc Chelators; 7.1. Mechanisms of HDAC-Induced Anticancer Effects; 7.2. Hydroxamic Acid-Based Inhibitors: Vorinostat and Panobinostat; 7.3. Benzamide-Based HDAC Inhibitor: Entinostat; 7.4. Cyclic Tetrapeptide-Based Inhibitor: Romidepsin.
|
| 520 |
|
|
|a Advances in Cancer Research provides invaluable information on the exciting and fast-moving field of cancer research. Here, once again, outstanding and original reviews are presented on a variety of topics.
|
| 650 |
|
0 |
|a Cancer
|x Research.
|
| 650 |
|
7 |
|a HEALTH & FITNESS
|x Diseases
|x General.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Clinical Medicine.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Diseases.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Evidence-Based Medicine.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Internal Medicine.
|2 bisacsh
|
| 650 |
|
7 |
|a Cancer
|x Research.
|2 fast
|0 (OCoLC)fst00845497
|
| 655 |
|
4 |
|a Electronic books.
|
| 700 |
1 |
|
|a Tew, Kenneth D.,
|e editor.
|
| 700 |
1 |
|
|a Fisher, Paul B.,
|e editor.
|
| 776 |
0 |
8 |
|i Print version:
|a Tew, Kenneth D.
|t Advances in Cancer Research.
|d : Elsevier Science, ©2016
|z 9780128047897
|
| 830 |
|
0 |
|a Advances in Cancer Research ;
|v v. 130.
|
| 856 |
4 |
0 |
|u https://www.sciencedirect.com/science/bookseries/0065230X/130
|z Full Text via HEAL-Link
|
